Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAO probe looks for FDA mishandling in heparin cases

This article was originally published in Scrip

Executive Summary

US Representative Joe Barton, ranking member of the House Energy and Commerce Committee, has requested that the Government Accountability Officeconduct a thorough review of the US FDA's handling of the heparin saga. Committee investigators have discovered evidence suggesting gaps and discrepancies in the agency's assessment of deaths associated with Baxter International's heparin. Specifically, there are questions on whether the agency made an effort to use all of the tools that could have helped it establish a causal link, the November 19th letter stated.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel